ArticleFrontiers in immunology2022

Generation of a High-Affinity Nanobody Against CD147 for Tumor Targeting and Therapeutic Efficacy Through Conjugating Doxorubicin.

Rifei Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.